InvestSMART

Imugene Limited (ASX: IMU) - ETF Exposure

- Current share price for IMU : $0.033

Imugene Limited (IMU) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The Company's unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

IMU General Information +

ASX Code IMU
Website http://www.imugene.com
Industry/Sector Biotechnology
Market Cap ($M) 18
IMU Share Price $0.033
Day High $0.034
Day Low $0.033
Last Close $0.033
IMU Share Price Movement - ( No change )
Prices as at 16:40, 3 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Imugene Limited (IMU) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Imugene Limited (IMU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Imugene Limited (IMU) price-sensitive announcements

IMU - Quarterly Activities/Appendix 4C Cash Flow Report
Imugene Limited’s Quarterly Activities and Appendix 4C Cash Flow Report for the quarter en
Imugene Limited (IMU)
30 Oct 2026 | 9:43 AM
IMU - Further Responses in azer-cel Phase 1b Trial
Imugene Limited announced further positive results from its ongoing open-label Phase 1b az
Imugene Limited (IMU)
19 Oct 2026 | 9:38 AM
IMU - azer-cel BTKi Cohort Reports new Complete & Partial Response
Imugene Limited announced updated results from Cohort 3 of its ongoing Phase 1b azer-cel t
Imugene Limited (IMU)
5 Oct 2026 | 8:56 AM
IMU - Appendix 4E and Annual Report
Imugene Limited’s Appendix 4E and Annual Report for the financial year ended 30 June 2026
Imugene Limited (IMU)
28 Aug 2026 | 5:28 PM

Imugene Limited (IMU) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Positive amendments to Convertible Notes 3 Nov 2026 9:47AM $0.034 $0.033 fallen by 2.94%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2026 9:43AM $0.038 $0.033 fallen by 13.16%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Further Responses in azer-cel Phase 1b Trial 19 Oct 2026 9:38AM $0.036 $0.033 fallen by 8.33%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Notification of cessation of securities - IMU 16 Oct 2026 4:15PM $0.036 $0.033 fallen by 8.33%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Application for quotation of securities - IMU 15 Oct 2026 9:48AM $0.036 $0.033 fallen by 8.33%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $18 Application for quotation of securities - IMU 14 Oct 2026 2:56PM $0.036 $0.033 fallen by 8.33%

IMU Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2028F C2 -$6.00 -25.00% 0.00 0.00 0.00% 0.0%
2027F C2 -$8.00 -69.40% 0.00 0.00 0.00% 0.0%
2026A -$85.18 -$26.10 -17.20% 0.00 0.00 0.00% 0.0%

IMU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2026 A 2027 F 2028 F 2026 A 2027 F 2028 F 2026 A 2027 F 2028 F
CSL Limited (CSL) $96,534M 0.7309 -0.4395 0.0602 12.4623 22.2350 20.9730 2.11% 2.12% 2.19%
Imugene Limited (IMU) $19M -0.1724 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,811M -0.4501 0.0000 0.0000 0.0000 0.0000 981.8182 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,871M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,452M -1.3893 0.0000 -0.5230 0.0000 154.0636 322.9630 0.00% 0.00% 0.00%

IMU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.52 0.00
Market 0.30 13.10 1.02 0.74
Sector 0.76 34.60 2.26 2.03

IMU Directors

Name Position Start Date
Mr Paul Alex Hopper Executive Chairman, Executive Director 31 Oct 2012
Mr Michael John Kotsanis Non-Executive Director 30 Jun 2026
Dr Lesley Russell Non-Executive Director 23 Apr 2019
Dr Charmaine Hilary Gittleson Non-Executive Director 30 Jun 2026
Dr Jakob Dupont Non-Executive Director 7 Sep 2022
Ms Kim Drapkin Non-Executive Director 21 Jun 2023

Imugene Limited (IMU) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 Aug 2026 HOPPER, Paul Buy Direct Shares 947,369 $0.095 $90,000.055
14 May 2026 CHONG, Leslie (Mi Ok) Buy Direct Shares 355,164 $0.103 $36,404.310
14 May 2026 HOPPER, Paul Buy Direct Shares 180,000 $0.104 $18,648.000

See all changes in directors' interest & trades for Imugene Limited (IMU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMU Management

Name Position
Darren Keamy Chief Financial Officer,Company Secretary
Dr John Byon Other Corporate Officer

IMU Calendar of Events

Date Event
27 August 2027 Report (Annual)
27 August 2027 Report (Prelim)
24 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.